Zacks Research Forecasts Reduced Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Investment analysts at Zacks Research cut their Q3 2025 earnings estimates for Zimmer Biomet in a research report issued on Monday, November 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $1.95 per share for the quarter, down from their prior forecast of $1.98. The consensus estimate for Zimmer Biomet's current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet's FY2025 earnings at $8.48 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.20 EPS and FY2026 earnings at $9.13 EPS.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company's revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business posted $1.65 EPS.

Other research analysts also recently issued research reports about the stock. Royal Bank of Canada increased their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their price target on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating on the stock in a research note on Monday, September 16th. UBS Group lowered their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating on the stock in a research note on Thursday, August 8th. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a report on Tuesday, October 1st. Finally, Raymond James reduced their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a report on Monday, October 14th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of "Hold" and a consensus target price of $123.22.

Zimmer Biomet Stock Performance

ZBH traded up $1.28 during midday trading on Wednesday, hitting $111.92. 132,269 shares of the company traded hands, compared to its average volume of 1,494,307. The company's 50-day moving average is $106.95 and its 200 day moving average is $109.47. Zimmer Biomet has a 52 week low of $101.47 and a 52 week high of $133.90. The firm has a market capitalization of $22.28 billion, a PE ratio of 21.03, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Monday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is currently 18.25%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet in the 3rd quarter worth about $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet during the second quarter worth approximately $33,000. Finally, Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the third quarter valued at approximately $35,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.